2 not yet recruiting, 1 enrolling by invitation, 1 recruiting, 1 terminated. 3 Phase 2, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Not yet recruiting 2, Terminated 1 |
| Early Phase 1 | 1 | Unknown 1 |
| Not applicable | 1 | Enrolling by invitation 1 |
Follow Dup15Q Syndrome: new trials by email Literature Review of Dup15Q Syndrome trials Research Report on Dup15Q Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Study of Basmisanil in Children and Adolescents With Dup15q Syndrome Basmisanil, Placebo - Dup15Q Syndrome | Phase 2 | Not yet recruiting | Newleos Therapeutics, Inc. | 30 | 2026-12-01 | 2026-09-29 |
| Investigating the Therapeutic Efficacy of All-trans Retinoic Acid in Autism Spectrum Disorder Patients With 15q11-13 Duplication Syndrome ATRA - Dup15q Syndrome, Autism Spectrum Disorder | Phase 2 | Not yet recruiting | Second Affiliated Hospital, Zhejiang University, School of Medicine | 90 | 2025-09-01 | 2025-07-23 |
| Structural-functional Connectome in Drug-resistant Epilepsies and Neurodevelopmental Syndromes With Epilepsy High Density EEG recording, Rey Complex Figure Test - Epilepsy, Angelman Syndrome | Recruiting | IRCCS Eugenio Medea | 120 | 2024-02-13 | 2024-04-09 | |
| A Study to Evaluate the Safety and Efficacy of Basmisanil Treatment in Children Aged 2-14 Years With Dup15q Syndrome Basmisanil, Placebo - Dup15q Syndrome | Phase 2 | Terminated | Hoffmann-La Roche | 7 | 2022-12-16 | 2026-08-18 |
| A Clinical Study Evaluating the Efficacy and Safety of Retinoic Acid in Patients With 15q11-q13 Duplication Syndrome Retinoic acid - Autism, Treatment Adherence | Early Phase 1 | Unknown | Second Affiliated Hospital, Zhejiang University, School of Medicine | 20 | 2022-04-01 | 2022-03-16 |
| Parent and Infant Inter(X)Action Intervention (PIXI) Parent-Infant Inter(X)action Intervention (PIXI) - Fragile X Syndrome, Angelman Syndrome | Not applicable | Enrolling by invitation | RTI International | 120 | 2018-11-30 | 2026-07-13 |
Angelman Syndrome (2) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Chromosome 15q, trisomy (1) · Developmental Disabilities (1) · DiGeorge Syndrome (1) · Down Syndrome (1) · Epilepsy (1) · Fragile X Syndrome (1) · Klinefelter Syndrome (1) · Muscular Dystrophy, Duchenne (1) · Polyposis Syndrome, Hereditary Mixed, 1 (1) · Prader-Willi Syndrome (1) · Rett Syndrome (1) · Smith-Magenis Syndrome (1)
Mental Disorders (3) · Neurodevelopmental Disorders (3) · Abnormalities, Multiple (2) · Central Nervous System Diseases (2) · Child Development Disorders, Pervasive (2) · Chromosome Disorders (2) · Congenital Abnormalities (2) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (2) · Genetic Diseases, Inborn (2) · Imprinting Disorders (2) · Movement Disorders (2) · Nervous System Diseases (2) · 22q11 Deletion Syndrome (1) · Aortic Stenosis, Supravalvular (1) · Aortic Valve Disease (1)
basmisanil (2) · Tretinoin (1)
Second Affiliated Hospital, Zhejiang University, School of Medicine (2) · Hoffmann-La Roche (1) · IRCCS Eugenio Medea (1) · Newleos Therapeutics, Inc. (1) · RTI International (1)
United States (3) · China (2) · Italy (1) · Spain (1) · United Kingdom (1)
Anne Wheeler, PhD (1) · Gian Marco Duma (1)